Drugs / GC310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07173933 | Oct 2025 → Apr 2027 expected | Wilson disease | GeneCradle Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07173933 ↗ |
| Action | Restore | “delivering a functional copy of the truncated human ATP7B gene” NCT07173933 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene” NCT07173933 ↗ |
| Route | Intravenous | “Participants will be administrated GC310 intravenously” NCT07173933 ↗ |
| Target | ATP7B | “GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene” NCT07173933 ↗ |